| Vivus: Is the Ship Sinking? KLLJ Investments submits: Ask any of the major analysts on the buy-side of Vivus (VVUS,) and you will hear that Qnexa is the next mega-blockbuster. Its 37lb’s of weight loss is so impressive, it is sure to be a multi-billion dollar drug. Wall Street has driven up the price from a 52-week low of $4.18 all the way up to a recent high of $13.68. Even $13.68 is cheap if you are talking about a mega-blockbuster! In my blog entry regarding who will be the First Line Therapy for Obesity, I discussed many of the reasons why Qnexa won’t be that drug and why.It seems that the Vivus insider who should have the most confidence on the success of Qnexa agrees with me. VVUS filed today yet another Form 4 for Leland Wilson, this time selling another 50,000 shares at a pre-determined price of $13. Basically, Leland had decided that $13 was a very fair price for VVUS, generous even perhaps, so he filed a 105b-1 that said when VVUS hits $13, I’ll sell 50,000 shares. This follows major selling of VVUS by the CEO in 2009, before and after Phase III results for Qnexa came out. These include the following transactions.Complete Story » seekingalpha.com |
Pushing Men to See the Doctor Men are less likely than women to get checkups, but more likely to be hospitalized with preventable illnesses. Now, public-health officials are trying to change that. online.wsj.com |
Clarient Can Profit From Rise of Individualized Medicine M.E. Garza submits: This small-cap company may be poised to be a long-term leader in cancer diagnostics and molecular testing. It combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient Inc. (CLRT) has a state-of-the-art commercial cancer laboratory, providing the most advanced oncology testing and diagnostic services. It's also developing new, proprietary “companion” diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient has a wonderful and comparatively inexpensive series of cancer diagnostic platforms that enables clinicians to determine the most effective therapies available for cancers having various genetic expressions. Its sales have been increasing at up to 20% a year compounded. Much of CLRT’s IP comes from its acquistion of Applied Genomics, Inc in December 2009. Complete Story » seekingalpha.com |
'Grade A' Egg Stamp Isn't What It Seems Many consumers wrongly believe the 'USDA Grade A' shield on egg cartons means they've been inspected for safety. In fact, the shield merely means the department has checked that the eggs are the correct color and size. online.wsj.com |
Amylin, Alkermes Hit Hard on Surprise Bydureon Rejection Other GLP-1s Coming Up Fast About the only good news for Amylin Pharmaceuticals Inc. Wednesday was that investors were unlikely to pay mind to the fact that third-quarter sales of diabetes drug Byetta (exenatide) missed analyst expectations, as shares of the San Diego-based biotech were hammered on a complete response letter and the prospect of a two-year delay for its once-weekly version of the GLP-1 agonist.Complete Story » seekingalpha.com |